lancet-header

Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.

Heavy Bleedings and Other Menstrual Disturbances in 18- to 30-Year-Old Women after COVID-19 Vaccination

37 Pages Posted: 19 Jan 2023

See all articles by Lill Trogstad

Lill Trogstad

Norwegian Institute of Public Health - Department of Method Development and Analytics

Ida Laake

Norwegian Institute of Public Health - Department of Method Development and Analytics

Anna Robertson

Norwegian Institute of Public Health - Department of Method Development and Analytics

Siri Mjaaland

Norwegian Institute of Public Health - Department of Method Development and Analytics

Ida Henriette Caspersen

Norwegian Institute of Public Health - Centre for Fertility and Health

Lene Juvet

Norwegian Institute of Public Health - Department of Method Development and Analytics

Per Magnus

Norwegian Institute of Public Health - Centre for Fertility and Health

Kristine Blix

Norwegian Institute of Public Health - Department of Method Development and Analytics

Berit Feiring

Norwegian Institute of Public Health - Department of Method Development and Analytics

More...

Abstract

Background: Many signals of menstrual disturbances as possible side effects of vaccination against COVID-19 have been reported. Our objective was to estimate the association between vaccination and the occurrence of such disturbances among women aged 18-30 years in Norway.

Methods: We used electronic questionnaires to collect reports of menstrual disturbances from 3972 women aged 18-30 years, participating in the population-based Norwegian Young Adult Cohort. We estimated the relative risk of menstrual disturbances according to vaccination using a self-controlled case-series design. We examined the occurrence of disturbances before and after both the first and second doses of COVID-19 vaccine, vaccine type/brand, previous gynaecological conditions and use of contraception/ hormone treatment.

Findings: The relative risk of reporting a heavier bleeding than usual during the first menstrual cycle after the first vaccine dose was 1.90 (95% CI: 1.69-2.13), while it was 1.84 (1.66-2.03) after the second dose. Increased risks of other menstrual disturbances after vaccination were also observed. We found no significant differences in the relative risk of menstrual disturbances according to vaccine type/brand, hormonal contraception status nor to the presence of gynecological condition(s).

Interpretation: Menstrual disturbances were generally common regardless of vaccination. We found a significant increase in menstrual disturbances after vaccination, particularly for heavier bleeding than usual, longer duration and for short interval between menstruations. In the future, menstrual characteristics should be routinely included in vaccine trials. Potential mechanisms for the observed disturbances should be explored.

Funding: This work was supported by the Norwegian Ministry of Health through a programme for corona vaccination surveillance.

Declaration of Interest: We declare no competing interests.

Ethical Approval: The study was approved by the Regional Ethics Committee South East Norway, no. 229359, 19 February 2021.

Keywords: Menstrual disturbances, COVID-19 vaccines, cohort study

Suggested Citation

Trogstad, Lill and Laake, Ida and Robertson, Anna and Mjaaland, Siri and Caspersen, Ida Henriette and Juvet, Lene and Magnus, Per and Blix, Kristine and Feiring, Berit, Heavy Bleedings and Other Menstrual Disturbances in 18- to 30-Year-Old Women after COVID-19 Vaccination. Available at SSRN: https://ssrn.com/abstract=4326798 or http://dx.doi.org/10.2139/ssrn.4326798

Lill Trogstad (Contact Author)

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Norway

Ida Laake

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Norway

Anna Robertson

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Siri Mjaaland

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Ida Henriette Caspersen

Norwegian Institute of Public Health - Centre for Fertility and Health ( email )

Lene Juvet

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Per Magnus

Norwegian Institute of Public Health - Centre for Fertility and Health ( email )

Kristine Blix

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Berit Feiring

Norwegian Institute of Public Health - Department of Method Development and Analytics ( email )

Click here to go to TheLancet.com

Paper statistics

Downloads
100
Abstract Views
490
PlumX Metrics